Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare

Supreme Court Rejects Big Pharma Appeals Challenging Medicare Price Negotiations

Supreme Court rejects Big Pharma appeals – On Monday, the U.S. Supreme Court turned down appeals from major pharmaceutical companies seeking to overturn a program designed to cut costs for Medicare and taxpayers. The decision, made without explanation, upheld the legality of Medicare’s negotiated drug pricing initiative, which was enacted in 2022 and has already begun saving billions. The program allows the federal government to negotiate prices for specific medications, a move that has drawn fierce opposition from drugmakers and their allies for three years. With the Supreme Court’s rejection, the program remains in place, pending further legal challenges.

The 2022 Inflation Reduction Act and Its Impact

The core of the dispute lies in a provision of the 2022 Inflation Reduction Act, which granted Medicare the authority to negotiate prices for certain drugs. This marks the first time the program has been able to directly lower costs for medications covered under federal health insurance. Critics argue the law represents government overreach, while supporters see it as a necessary step to combat the rising expenses of prescription drugs. The Supreme Court’s decision to reject the appeals suggests it has not found sufficient grounds to invalidate the program, even as the pharmaceutical industry continues its legal push.

Financial Savings and the Industry’s Response

Medicare’s price negotiation program has already demonstrated its effectiveness. In its first round, 10 drugs were reviewed, leading to a projected $6 billion in federal savings and a $1.5 billion reduction in out-of-pocket costs for seniors. These savings came into effect in January 2024, with notable examples including Farxiga, a diabetes and kidney disease medication by AstraZeneca, and Eliquis, a blood thinner from Bristol Myers Squibb. Drugmakers like AstraZeneca and Janssen claim the process resulted in a 68% discount for Farxiga compared to its list price, but they argue the program violates their constitutional rights.

Legal Arguments and Constitutional Concerns

Pharmaceutical companies have framed their opposition as a constitutional battle. They assert that the program forces them into “sham negotiations” without fair compensation, which they say violates their due process rights. Additionally, the companies argue the law infringes on their First Amendment freedoms by compelling them to adopt the government’s narrative about drug pricing. These claims were dismissed by lower courts, which emphasized that participation in Medicare is voluntary and that companies can withdraw from the program if they disagree with the negotiated rates.

The Supreme Court’s Role and the Industry’s Disadvantage

The Supreme Court often relies on lower court splits to decide whether to grant a case, but the pharmaceutical industry faced a challenge in this instance. Since no lower courts had ruled in their favor, the companies could not demonstrate a constitutional disagreement among federal judges. This lack of a divided opinion likely contributed to the Court’s decision to reject their appeals. Andrew Twinamatsiko, director of the Center for Health Policy and the Law at Georgetown University’s O’Neill Institute, noted that the legal arguments presented by the industry were “weak in law” and “grasping at constitutional straws.”

“The challenges that the industry presented were weak in law. They were grasping at constitutional straws,” Twinamatsiko said. He and a colleague wrote in a Health Affairs article in March that federal courts have “spoken unequivocally” on the constitutional issues raised by the pharmaceutical companies, reinforcing the program’s validity.

Program Details and Future Rounds

The drug pricing negotiations are based on a list of medications with the highest Medicare spending, ensuring the most expensive drugs are targeted. The second round, covering 15 drugs, is expected to save the federal government $12 billion and reduce seniors’ out-of-pocket expenses by $685 million once prices take effect next January, according to the Trump administration. Negotiations for a third round are currently underway, with more drugs likely to be added in the coming months. These projections highlight the program’s potential to significantly ease financial strain on Medicare beneficiaries and the broader federal budget.

Constitutional Claims and Industry’s Frustration

One of the key legal arguments from drugmakers is that the program constitutes an unconstitutional “taking” of their property, violating the Fifth Amendment. They claim that if they refuse to accept the negotiated prices, they must either withdraw from Medicare and Medicaid—two of the largest markets for prescription drugs—or face hefty excise taxes. This, they argue, forces them into an unfair agreement without proper compensation. However, courts have countered that companies retain the right to opt out, even if they face financial consequences.

The Debate Over Government Price Fixing

The program has been a focal point of debate since its inception, with critics arguing that it amounts to government price fixing. They contend that Medicare’s ability to negotiate prices could limit the market power of pharmaceutical firms, potentially reducing their profits. Despite these concerns, the law’s supporters maintain that the program is a fair mechanism to ensure affordability for seniors and taxpayers. The Supreme Court’s decision to side with the program suggests that the government’s authority to negotiate prices under Medicare is robust, at least in the eyes of the highest court.

Broader Implications for Drug Pricing

The program’s success has sparked discussions about the long-term effects of government intervention in drug pricing. In 2021 alone, the federal government spent over $250 billion on Medicare-covered medications, underscoring the urgency of cost-cutting measures. While the pharmaceutical industry has resisted, the program’s savings could set a precedent for future negotiations. However, the industry remains determined, with ongoing lawsuits in multiple U.S. districts challenging the law’s implementation. The outcome of these cases may influence how Medicare continues to reshape the landscape of prescription drug costs in the years ahead.

Conclusion: A Shift in the Legal Landscape

With the Supreme Court’s rejection of the appeals, the legal battle over Medicare’s drug pricing negotiations appears to be drawing to a close. The decision affirms the program’s constitutionality and reinforces the government’s ability to negotiate prices for medications, even as the industry continues to push back. The savings from the first two rounds of negotiations demonstrate the program’s effectiveness, and the third round is poised to build on that success. As the debate over prescription drug costs intensifies, this ruling marks a significant victory for federal efforts to curb expenses and improve affordability for millions of Americans.